Asia-Pacific Eyelid Surgery Blepharoplasty Market Growth Prospects 2024-2032
According to Triton’s research report, the eyelid surgery blepharoplasty market in the Asia-Pacific is estimated to expand in terms of revenue at a CAGR of 7.45% over the forecast years 2024-2032.
According to new data from the International Society of Aesthetic Plastic Surgery, Asian countries accounted for over 20% of the 1.3 million eyelid procedures performed globally. In the Asia-Pacific region, upper eyelid surgery remains the most popular procedure, driven by cultural preferences for defined eyes and the high prevalence of single eyelids or mono eyelids. Costs for these surgeries vary widely across the region, influenced by factors such as city tier, surgeon reputation, and healthcare infrastructure. The rising influence of celebrities and social media, especially among younger generations, has further fueled interest in eyelid procedures. With increasing government investments in regulatory oversight and advancements in medical technology, the demand for blepharoplasty surgery is expected to experience sustained growth in the Asia-Pacific region.
The countries analyzed in this region include China, Australia & New Zealand, ASEAN Countries, Japan, South Korea, India, Rest of Asia-Pacific.
Japan leads with a major market share, recording nearly $362.89 million in 2023.
- Eyelid surgery consistently ranks among the top five aesthetic procedures globally and is the most common cosmetic surgery in Japan, according to ISAPS data.
- In 2020, Japan reported 222,642 total surgical aesthetic procedures, with eyelid surgeries accounting for 143,921—an impressive 64.6% of the total. The country performed 1.1 million aesthetic procedures in 2021, with 10% being eyelid surgeries, reinforcing its position as a leading market for this procedure.
- Thus, a strong cultural preference for defined eyelids, coupled with high procedure rates and sustained interest, highlights a steady demand for eyelid surgeries in Japan, driving consistent growth in this segment.
Eyelid Surgery Blepharoplasty Market Forecast for China
Double eyelid blepharoplasty has long been the most popular cosmetic surgery in China since over 40% of the population has single eyelids. Common features such as upper eyelid puffiness, narrow palpebral fissures, and medial epicanthal folds drive demand for this procedure. Costs for eyelid surgeries vary significantly, with high-end hospitals in cities like Shanghai and Beijing charging $3,000 or more. The rise of celebrity culture and influencers has fueled the demand for blepharoplasty surgery, particularly among younger generations. Meanwhile, government investments in oversight and board certification aim to enhance safety and sustain the market growth.
The eyelid surgery blepharoplasty market is segmented by gender, procedure type, product type, and end-user. Based on gender, it is further classified into male and female. Females dominate the eyelid surgery blepharoplasty market, accounting for 80-90% of procedures across most regions. Adoption rates vary widely by region, often reflecting differences in disposable income. Key demographics include women aged 35-60, with growing interest from younger women aged 18-34, driven by social media and appearance-related concerns. This younger demographic signals potential long-term growth in demand.
Contender Analysis in the Eyelid Surgery Blepharoplasty Market:
LightScalpel manufactures specialized lasers designed to treat drooping eyelids and rejuvenate aging eyelid skin. Their UltraLift™ carbon dioxide laser system provides an ergonomic solution tailored to individual patient anatomy. Recent enhancements have improved the speed and precision of laser treatments for the delicate eye area. The company is headquartered in Washington, United States.
From January 2024, the company announced that it will now oversee all of the sales and marketing operations in Australia directly from its headquarters.
Other key contenders in the market include London Bridge Plastic Surgery, Sisram Medical Ltd, Osheru LLC, Sciton Inc, and Surgical Holdings.